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Abstract
Background: This study was performed to compare the effects of three different lipid-lowering therapies (statins,
ezetimibe, and colestimide) on lipoprotein lipase and endothelial lipase masses in pre-heparin plasma (pre-heparin
LPL and EL mass, respectively) from patients with familial hypercholesterolemia (FH). FH is usually treated by
coadministration of these three drugs.
Methods: The pre-heparin LPL and EL masses were measured in fresh frozen plasma drawn and stored at various
time points during coadministration of the three drugs from patients with heterozygous FH harboring a single
mutation in the LDL receptor (n = 16, mean age 63 years). The patients were randomly divided into two groups
based on the timing when ezetimibe was added.
Results: Plasma LPL mass concentration was significantly reduced by rosuvastatin at 20 mg/day (median = 87.4
[IQR: 71.4–124.7] to 67.5 [IQR: 62.1–114.3] ng/ml, P < 0.05). In contrast, ezetimibe at 10 mg/day as well as colestimide
at 3.62 g/day did not alter its level substantially (median = 67.5 [IQR: 62.1–114.3] to 70.2 [IQR: 58.3–106.2], and to
74.9 [IQR: 55.6–101.3] ng/ml, respectively) in the group starting with rosuvastatin followed by the addition of
ezetimibe and colestimide. On the other hand, the magnitude in LPL mass reduction was lower in the group
starting with ezetimibe at 10 mg/day before reaching the maximum dose of 20 mg/day of rosuvastatin. Plasma EL
mass concentration was significantly increased by rosuvastatin at 20 mg/day (median = 278.8 [IQR: 186.7–288.7] to
297.0 [IQR: 266.2–300.2] ng/ml, P < 0.05), whereas other drugs did not significantly alter its level.
Conclusion: The effects on changes of LPL and EL mass differed depending on the lipid-lowering therapy, which
may impact the prevention of atherosclerosis differently.
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Background
Lipoprotein lipase (LPL) and endothelial lipase (EL)
hydrolyze triglyceride (TG) in circulating chylomicrons
and very low-density lipoprotein (VLDL) on the surface
of endothelial cells [1]. It has been demonstrated that a
reduced concentration of plasma LPL mass is associated
with an increased risk of coronary artery disease [2, 3].
Several studies have demonstrated that plasma LPL mass
concentration could be altered by drug manipulations,
such as fibrate, insulin sensitizer, and statins in patients
with diabetes, potentially affecting the progression of their
atherosclerosis [4–6]. In addition, recent genetic studies
have suggested that genetic modulators of LPL mediate
cardiovascular risk. For example, loss-of-function muta-
tions in apolipoprotein C3 (APOC3), which is an inhibitor
of LPL, decrease the risk of coronary artery disease (CAD)
[7], while loss-of-function mutations in apolipoprotein A5
(APOA5), which is an activator of LPL, increases the risk
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of CAD [8]. In contrast, large-scale clinical trials assessing
the efficacy of HDL cholesterol-raising therapies have
failed [9, 10] based on the neutral impact of HDL choles-
terol concentration on CAD estimated by Mendelian
randomization studies [11, 12]. Accordingly, targeting
plasma LPL (and EL) concentrations, rather than plasma
HDL cholesterol concentration, could be much more rea-
sonable in terms of preventive cardiology. However, no
study has yet assessed the changes in plasma lipase mass
concentration during lipid-lowering therapy in patients
with familial hypercholesterolemia (FH), which usually re-
quires the coadministration of different types of such
drugs [13]. Therefore, we compared the effects of three
different lipid-lowering therapies (statins, ezetimibe, and
colestimide) on LPL and EL mass in pre-heparin plasma




The study population consisted of patients with hetero-
zygous FH who participated in a previous clinical trial
conducted as a prospective open randomized study to
investigate the efficacy and safety of coadministration of
rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and
granulated colestimide (3.62 g/day) at the maximum
doses permitted in Japan. All 17 subjects were heterozy-
gous with a confirmed LDL receptor gene mutation and
fulfilled our clinical diagnostic criteria for heterozygous
FH: patients with primary hyper-LDL cholesterolemia
(>160 mg/dl) with tendon xanthoma or those with first-
degree relatives with previously diagnosed heterozygous FH
showing primary hyper-LDL cholesterolemia (>160 mg/dl).
Exclusion criteria of the present study were FH patients
with a homozygous gene mutation, patients under LDL
apheresis therapy or any immunomodulatory medication,
patients with fasting serum triglyceride levels >500 mg/dl,
patients with hepatic disease, or patients within 12 weeks
after the onset of an acute myocardial infarction or stroke.
Details of this study have been described elsewhere [14],
and 16 of 17 patients whose fresh frozen plasma was avail-
able were included in this study. The subjects were di-
vided into two groups using a sealed envelope-based
method according to the timing when ezetimibe was
added at 10 mg/day. All participants were started on a 4-
week treatment with rosuvastatin at 5 mg/day followed by
another 4-week treatment of rosuvastatin at 10 mg/day.
The dose of rosuvastatin in group 1 was increased to
20 mg with an 8-week follow-up, whereas group 2 re-
ceived ezetimibe at 10 mg/day with an 8-week follow-up
(phase 1). After phase 1, group 1 received ezetimibe at
10 mg/day added to rosuvastatin for 8 weeks, whereas
in group 2 the doses of rosuvastatin were increased to
20 mg with an 8-week follow-up (phase 2). In phase 3,
groups 1 and 2 were given 3.62 g of granulated colesti-
mide (twice a day before meals, once in the morning
and once in the evening) added to the phase 2 treatment
regimen (Fig. 1).
Determination of LPL and EL mass concentrations
Fasting blood samples were drawn and stored at −80 °C
during the study period. Pre-heparin LPL concentrations
were determined with a highly sensitive and specific
ELISA kit (Code No.27184; IBL, Fujioka, Japan) [15, 16].
Fig. 1 Study design. The present study was conducted as a prospective open randomized study to investigate the efficacy and safety of
coadministration of rosuvastatin at 20 mg/day, ezetimibe at 10 mg/day, and granulated colestimide at 3.62 g/day. Any lipid-lowering agents had
been washed out≥ 4 weeks before entry into the study. Study subjects were divided into two groups by an envelope-based method to elucidate
the secondary end point of the present study: rosuvastatin at 20 mg/day (group 1) versus rosuvastatin at 10 mg/day coadministered with ezetimibe at
10 mg/day (group 2). The white, blue, pink, and purple arrows indicate baseline, second, third, and last blood sampling, respectively
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EL mass concentrations were determined using our
ELISA system (Code No. 27182; IBL) [17].
Biochemical analysis
Fasting blood samples were drawn for assays. Plasma
concentrations of total cholesterol, TG, and HDL choles-
terol were determined enzymatically as described previ-
ously [18]. Remnant-like particles (RLP) were determined
as described previously [19].
Statistical analysis
Categorical variables are expressed as percentages. Con-
tinuous variables with a normal distribution are shown
as means (± SD), and those with a skewed distribution
are shown as medians (interquartile [IQR]). The changes
in each lipase mass concentration were compared by
analysis of variance (ANOVA). All statistical analyses
were conducted using R. In all analyses, P < 0.05 was as-
sumed to indicate statistical significance.
Ethical considerations
This study was approved by the Ethics Committees of
Kanazawa University (Number: 1883–1) and Kanazawa
Medical University (Number: 272). All procedures were
performed in accordance with the ethical standards of
the responsible committee on human experimentation
(institutional and national) and with the Helsinki Declar-
ation of 1975, as revised in 2008. Informed consent for
genetic analyses was obtained from subjects with FH for
inclusion in the study.
Results
Baseline characteristics of study subjects
Sixteen Japanese subjects with heterozygous FH were
enrolled in the present study. Baseline characteristics
and concomitant drug therapies are listed in Table 1.
Five of six diabetic patients (28 %) that were under
hypoglycemic medical therapy had a glycohemoglobin
concentration < 7.0 %. No patients were treated with
insulin injection therapy. Dosages of coadministered
medications were kept constant during the entire study
period.
Changes in LPL mass during coadministration of three
drugs
In group 1, the LPL mass concentration was significantly
reduced by rosuvastatin at 20 mg/day (median = 87.4
[IQR: 71.4–124.7] to 67.5 [IQR: 62.1–.3] ng/ml, P < 0.05,
Fig. 2a), whereas ezetimibe at 10 mg/day as well as
colestimide at 3.62 g/day did not markedly alter its level
(median = 67.5 [IQR: 62.1–114.3] to 70.2 [IQR: 58.3–
106.2], and to 74.9 [IQR: 55.6–101.3] ng/ml, respectively,
P =NS, Fig. 2a). Similar trends were observed in group
2, in which the statistical significance of the reduction
during phase 1 was diminished using combination
therapy consisting of rosuvastatin at 10 mg/day and eze-
timibe at 10 mg/day (median = 79.3 [IQR: 58.8–85.0] to
77.5 [IQR: 60.0–84.6] ng/ml, P =NS, Fig. 3a). On the
other hand, the significant reduction in LPL mass con-
centration achieved by adding colestimide at 3.62 g/day
was replicated in group 2 (median = 81.9 [IQR: 47.9–
87.0] to 75.1 [IQR: 43.3–85.5] ng/ml, P < 0.05, Fig. 3a).
Changes in EL mass during coadministration of three
drugs
In group 1, the EL mass concentration was significantly
increased by rosuvastatin at 20 mg/day (median = 278.8
[IQR: 186.7–288.7] to 297 [IQR: 266.2–300.2] ng/ml, P
< 0.05, Fig. 2b), whereas ezetimibe at 10 mg/day as well
as colestimide at 3.62 g/day did not markedly change its
level (median = 297 [IQR: 266.2–300.2] to 241.8 [IQR:
232.0–305.6], and to 243.5 [IQR: 231.6–298.5] ng/ml,
respectively, P = NS, Fig. 2b). In group 2, combination
therapy with rosuvastatin at 10 mg/day and ezetimibe
at 10 mg/day also increased its level significantly (me-
dian = 250.6 [IQR: 175.6–351.8] to 300.3 [IQR: 238.0–
375.0] ng/ml, P < 0.05, Fig. 3b). On the other hand,
there were no significant changes in EL mass concen-
tration when ezetimibe was added at 10 mg/day and
colestimide at 3.62 g/day (median = 300.3 [IQR: 238.0–
375.0] to 369.2 [IQR: 212.0–451.2], and to 296.3 [IQR:
231.7–424.1] ng/ml, respectively, P =NS, Fig. 3b).
Association between plasma lipids and lipase mass
We investigated the associations between changes in
LPL/EL and those in LDL cholesterol, TG, or RLP choles-
terol during each phase. There were no significant associa-
tions between the changes in LPL mass concentrations
and those in lipids (Additional file 1: Figures S1–S6).
Table 1 Baseline characteristics
All (n = 16) Group 1 (n= 9) Group 2 (n= 7)
Age (yr) 63 ± 10 60 ± 11 68 ± 7
Male (n,%) 11 (69 %) 4 (44 %) 5 (71 %)
Body mass index (kg/m2) 23.7 ± 2.0 23.1 ± 1.9 24.5 ± 1.9
Total cholesterol (mg/dl) 380 ± 42 394 ± 56 364 ± 51
Triglyceride (mg/dl) 95 [84–127] 95 [88–126] 91 [68–136]
HDL cholesterol (mg/dl) 46 ± 10 49 ± 14 43 ± 6
LDL cholesterol (mg/dl) 299 ± 48 309 ± 46 283 ± 48
RLP cholesterol (mg/dl) 8.9 ± 3.3 8.7 ± 3.5 9.2 ± 3.0
Hypertension (n, %) 8 (50 %) 3 (33 %) 5 (71 %)
Diabetes (n, %) 6 (38 %) 3 (33 %) 3 (43 %)
Smoking (n, %) 1 (6 %) 0 (0 %) 1 (14 %)
Coronary artery
disease (n, %)
9 (56 %) 4 (44 %) 5 (71 %)
RLP remnant-like particle
Tada et al. Lipids in Health and Disease  (2016) 15:66 Page 3 of 6
Significant associations between the changes in EL
mass concentrations and TG/RLP cholesterol were
observed during phase 2 in group 2 (Additional file 1:
Figures S7–S12).
Discussion
We measured the pre-heparin LPL and EL mass at each
time point during coadministration of three drugs (statin,
ezetimibe, and colestimide) in patients with heterozygous
FH harboring a single mutation in the LDL receptor to
compare the effects of these drugs on the plasma lipase
mass concentration. Our results indicate that (1) statin
and colestimide significantly reduced plasma LPL mass,
but ezetimibe did not alter its level; (2) statin significantly
increased plasma EL mass, but ezetimibe and colestimide
did not change its level; (3) there was no clear association
between changes in lipase mass and changes in plasma
lipid levels.
Recent Mendelian randomization trials have suggested
that plasma TG is one of the causal factors for the devel-
opment of coronary artery disease, rather than merely a
marker [7, 20]. In addition, plasma TG level is one of
the residual risks in this statin era [21]. Accordingly, re-
assessment of TG-rich lipoprotein metabolism seems to
be a reasonable strategy to combat such residual risk. In
this regard, genetic studies have indicated that the LPL
and APOC3 pathway is strongly associated with plasma
TG as well as coronary artery disease, gathering a great
deal of attention as a novel therapeutic target. Increasing
plasma LPL concentration as well as reducing plasma
APOC3, rather than increasing plasma HDL cholesterol,
could be beneficial targets.
The results of one study that investigated the effect of
statins on changes in LPL mass concentration in patients
with diabetes showed results that were contrary to ours
[6]. This difference may have been because we used the
a b
Fig. 2 Lipase mass concentration during coadministration of three drugs in group 1. a LPL mass concentration. b EL mass concentration. White
indicates the baseline. Blue indicates the second blood sampling when rosuvastatin was administered at 20 mg/day. Pink indicates the third
blood sampling when rosuvastatin at 20 mg/day and ezetimibe at 10 mg/day were coadministered. Purple indicates the last blood sampling
when rosuvastatin at 20 mg/day, ezetimibe at 10 mg/day, and colestimide at 3.62 g/day were coadministered
a b
Fig. 3 Lipase mass concentration during coadministration of three drugs in group 2. a LPL mass concentration. b EL mass concentration. White
indicates the baseline. Blue indicates the second blood sampling when rosuvastatin at 10 mg/day and ezetimibe at 10 mg/day were
coadministered. Pink indicates the third blood sampling when rosuvastatin at 20 mg/day and ezetimibe at 10 mg/day were coadministered.
Purple indicates the last blood sampling when rosuvastatin at 20 mg/day, ezetimibe at 10 mg/day, and colestimide at 3.62 g/day
were coadministered
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maximum dose of rosuvastatin in patients with FH whose
TG-rich lipoprotein levels were shown to be impaired.
Our study has several limitations. First, the size of the
study population was small because of the rarity of the
disease (diagnosed genetic heterozygous FH). However,
we observed similar tendencies between the two groups
divided according to the timing of the initiation of ezeti-
mibe. Second, this study did not have a crossover design,
which could potentially lead to biased assessment of the dif-
ferences among drugs. Third, we measured pre-heparin lip-
ase mass levels instead of post-heparin levels, which could
potentially affect the results, especially LPL mass levels.
Conclusion
In conclusion, the effects on changes of LPL and EL mass
were different depending on the lipid-lowering therapy,
which may have different impacts on the preventive
effects of the therapy on atherosclerosis.
Additional file
Additional file 1: Associations between the changes in LPL/EL mass
and those in lipids. (PPTX 2501 kb)
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